BeiGene PE Ratio 2014-2024 | ONC
Current and historical p/e ratio for BeiGene (ONC) from 2014 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. BeiGene PE ratio as of January 03, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| BeiGene PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2025-01-03 |
180.82 |
|
0.00 |
| 2024-09-30 |
224.51 |
$-8.24 |
0.00 |
| 2024-06-30 |
142.67 |
$-5.08 |
0.00 |
| 2024-03-31 |
156.39 |
$-7.57 |
0.00 |
| 2023-12-31 |
180.36 |
$-8.50 |
0.00 |
| 2023-09-30 |
179.87 |
$-9.26 |
0.00 |
| 2023-06-30 |
178.30 |
$-16.66 |
0.00 |
| 2023-03-31 |
215.53 |
$-18.58 |
0.00 |
| 2022-12-31 |
219.94 |
$-19.48 |
0.00 |
| 2022-09-30 |
134.82 |
$-21.35 |
0.00 |
| 2022-06-30 |
161.85 |
$-20.42 |
0.00 |
| 2022-03-31 |
188.60 |
$-20.09 |
0.00 |
| 2021-12-31 |
270.93 |
$-15.16 |
0.00 |
| 2021-09-30 |
363.00 |
$-14.20 |
0.00 |
| 2021-06-30 |
343.19 |
$-14.55 |
0.00 |
| 2021-03-31 |
348.08 |
$-13.63 |
0.00 |
| 2020-12-31 |
258.39 |
$-19.02 |
0.00 |
| 2020-09-30 |
286.44 |
$-20.21 |
0.00 |
| 2020-06-30 |
188.40 |
$-20.51 |
0.00 |
| 2020-03-31 |
123.11 |
$-17.63 |
0.00 |
| 2019-12-31 |
165.76 |
$-15.74 |
0.00 |
| 2019-09-30 |
122.46 |
$-13.87 |
0.00 |
| 2019-06-30 |
123.95 |
$-11.29 |
0.00 |
| 2019-03-31 |
132.00 |
$-12.78 |
0.00 |
| 2018-12-31 |
140.26 |
$-12.00 |
0.00 |
| 2018-09-30 |
172.22 |
$-9.67 |
0.00 |
| 2018-06-30 |
153.73 |
$-4.60 |
0.00 |
| 2018-03-31 |
168.00 |
$-3.20 |
0.00 |
| 2017-12-31 |
97.72 |
$-2.44 |
0.00 |
| 2017-09-30 |
103.46 |
$-1.30 |
0.00 |
| 2017-06-30 |
45.00 |
$-4.92 |
0.00 |
| 2017-03-31 |
36.61 |
$-4.13 |
0.00 |
| 2016-12-31 |
30.36 |
$-3.83 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
